Form 4: Olema Pharmaceuticals Director Graham Walmsley Granted Stock Options

Olema Pharmaceuticals, Inc. Director and 10% Owner, Graham G. Walmsley, was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months.

Summary

• Graham G. Walmsley, a Director and 10% Owner of Olema Pharmaceuticals, Inc. (OLMA), was granted stock options.
• The grant occurred on June 11, 2025.
• The options are for 24,150 shares of common stock.
• The exercise price for these options is $4.08 per share.
• The options have an expiration date of June 11, 2035.
• The shares subject to the option will vest in 12 equal monthly installments starting from June 11, 2025, contingent on Mr. Walmsley's continuous service.
• Full vesting will occur on the date of the Issuer's next annual meeting of stockholders if not already fully vested, also subject to continuous service.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management/director interests with shareholders and incentivizes long-term performance. It's a standard compensation practice, so not overwhelmingly positive, but certainly not negative.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The vesting schedule encourages continuous service and commitment from a key board member.

Risks

• Vesting of options is contingent on continuous service, meaning the options could be forfeited if the director's service ceases before full vesting.
• The value of the options is dependent on the future stock price of Olema Pharmaceuticals, Inc. exceeding the exercise price of $4.08.

Future Outlook

The vesting schedule indicates a future commitment from the director, with options vesting monthly over 12 installments from June 11, 2025, or fully at the next annual meeting if not already vested, contingent on continuous service.

Industry Context

Stock option grants are a common form of equity compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key personnel, including directors, by aligning their financial interests with the company's long-term performance and shareholder value creation. This is a routine compensation event for a director.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in the U.S. public company landscape, particularly within growth-oriented sectors like biotechnology.
• While the specific number of options (24,150) and exercise price ($4.08) are specific to Olema Pharmaceuticals and its current valuation, the mechanism of equity compensation is consistent with industry benchmarks for director remuneration, which often includes a mix of cash and equity to foster long-term alignment.
• Without specific comparable director compensation packages from similar-sized biotech companies or those at a similar stage of development, a direct quantitative comparison is not feasible from this document alone. However, the structure of the grant, including a vesting schedule, is typical.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised in the future, but also potential for increased shareholder value if the director's incentives lead to improved company performance.

Next Steps

• Continued service of Graham G. Walmsley as a Director.
• Monthly vesting of the granted stock options over 12 installments from June 11, 2025.
• Potential full vesting at the next annual meeting of stockholders if not fully vested by then.

Key Dates

Recommendation

Keywords

Olema Pharmaceuticals, OLMA, Stock Option Grant, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Compensation, Graham G. Walmsley